Immusoft

Immusoft

Immusoft is a biotechnology company developing a platform for the insertion of therapeutic genes into immune cells for the treatment of a variety of genetic diseases.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

January 2019

Immusoft raises a $20,000,000 series B round from Mesa Verde Venture Partners, Breakout Ventures, RBV Capital and DEFTA Partners.

January 2018

Immusoft raises a $3,000,000 series B round from 600 Mile Challenge Fund.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Cam Gallagher

Chief Business Officer

Jason Fontenot

Chief Scientific Officer

Monika Swietlicka

Vice President of Regulatory Affairs

Scott McIvor

Chief Development Officer

Sean Ainsworth

Chief Executive Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.